PSTI - プルリステム・セラピュ―ティクス (Pluristem Therapeutics Inc.)

PSTIのニュース

   The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts  2021/07/27 11:48:32 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI ) (IPOed Thursday) Arvinas, Inc. (NASDAQ: ARVN ) BioNTech SE (NASDAQ: BNTX ) ( disclosed plans to make mRNA vaccine for malaria by 2022) Cassava Sciences, Inc. (NASDAQ: SAVA ) (announced positive data for SavaDx, an investigational diagnostic/biomarker to detect Alzheimer''s disease with a simple blood test) Eli Lilly and Company (NYSE: LLY ) Moderna, Inc. (NASDAQ: MRNA ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) NanoVibronix, Inc. (NASDAQ: NAOV ) (announced first shipment of its next generation pain management device, PainShield Plus) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Sight Sciences, Inc. (NASDAQ: SGHT ) (IPOed July 15) Translate Bio, Inc. (NASDAQ: TBIO ) (moved on positive analyst action) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 26) 23andMe Holding Co. (NASDAQ: ME ) AbCellera Biologics Inc.
   Global Hematopoietic Stem Cell Transplantation (HSCT) Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc  2021/07/23 22:05:49 Jumbo News
The report on Global Hematopoietic Stem Cell Transplantation (HSCT) Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains []
   The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street  2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
   Pluristem Therapeutics Inc Shares Approach 52-Week Low - Market Mover  2021/07/18 15:17:34 Kwhen Finance
Pluristem Therapeutics Inc (PSTI) shares closed today at 1.7% above its 52 week low of $3.50, giving the company a market cap of $112M. The stock is currently down 49.6% year-to-date, down 59.5% over the past 12 months, and down 75.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 106.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 739.8% The company's stock price performance over the past 12 months lags the peer average by 1322.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Pluristem Therapeutics Inc Shares Close in on 52-Week Low - Market Mover  2021/07/17 03:53:01 Kwhen Finance
Pluristem Therapeutics Inc (PSTI) shares closed today at 1.7% above its 52 week low of $3.50, giving the company a market cap of $112M. The stock is currently down 49.6% year-to-date, down 59.5% over the past 12 months, and down 75.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 103.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 739.8% The company's stock price performance over the past 12 months lags the peer average by 1060.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Pluristem Therapeutics Consensus Indicates Potential 39.2% Upside  2021/06/25 10:44:32 DirectorsTalk
Pluristem Therapeutics found using ticker (PSTI) have now 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 10 and 6 with a mean TP of 8.6. Given that the stocks previous close was at 6.18 this now indicates there is a potential upside of 39.2%. The day 50 moving average is 8.72 and the 200 day MA is 9.25. The market cap for the company is $173m. Find out more information at: /> [stock_market_widget type="chart" symbol="PSTI" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases.
   Cathie Woods ARK Invest Sells 194,000 Shares of Pluristem Therapeutics  2021/06/05 11:53:36 24/7 Wall street
   Pluristem CEO touts a new generation of medical treatments  2021/06/02 10:31:52 The Jerusalem Post
Yaky Yanay at Dubai conference: They put Israel on the map as an island of innovation
   Financings for May 25, 2021  2021/05/25 16:00:00 BioWorld
Med-tech firms raising money in public or private financings, including: Emboline, Noom, Pluristem, Rapid Medical.
   Pluristem Stock is Trading Higher After 20M Non-Dilutive Funding from European Investment Bank  2021/05/25 12:48:36 Benzinga
Pluristem Therapeutics Inc (NASDAQ: PSTI ) has received 20 million (approximately $24 million) from the European Investment Bank (EIB), the first disbursement of three tranches of funding. The disbursement reflects that Pluristem has achieved a key milestone in a previously Full story available on Benzinga.com
   Cathie Woods ARK Invest Sells 194,000 Shares of Pluristem Therapeutics  2021/06/05 11:53:36 24/7 Wall street
   Pluristem CEO touts a new generation of medical treatments  2021/06/02 10:31:52 The Jerusalem Post
Yaky Yanay at Dubai conference: They put Israel on the map as an island of innovation
   Financings for May 25, 2021  2021/05/25 16:00:00 BioWorld
Med-tech firms raising money in public or private financings, including: Emboline, Noom, Pluristem, Rapid Medical.
   Pluristem Stock is Trading Higher After 20M Non-Dilutive Funding from European Investment Bank  2021/05/25 12:48:36 Benzinga
Pluristem Therapeutics Inc (NASDAQ: PSTI ) has received 20 million (approximately $24 million) from the European Investment Bank (EIB), the first disbursement of three tranches of funding. The disbursement reflects that Pluristem has achieved a key milestone in a previously Full story available on Benzinga.com
   Pluristem rises 7% following 20M funding from European Investment Bank  2021/05/25 12:01:25 Seeking Alpha

calendar